Eficácia de esquemas terapêuticos baseados em bloqueadores competitivos de potássio (P-CABS) na erradicação de cepas de Helicobacter pylori resistentes

Helicobacter pylori infection is a severe public health issue, characterized by high prevalence in Latin America and a strong association with the development of gastric cancer. Given the growing bacterial resistance to conventional therapy based on proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs) emerge as a promising alternative. The present study aims to evaluate the efficacy of P-CABs, focusing on vonoprazan and tegoprazan, in the eradication of resistant H. pylori strains compared to PPIs. To this end, a literature review was conducted in the PubMed/MEDLINE, Embase, Cochrane, and Web of Science databases, encompassing publications particularly from the last 10 years. The results indicate that P-CABs promote faster, more potent, and sustained acid suppression without being subjected to interference from CYP2C19 polymorphisms. Vonoprazan-based regimens achieve overall eradication rates of 86% to 94%, outperforming PPIs, especially in clarithromycin-resistant strains (66% to 81% efficacy against 32% to 40% for PPIs). Highdose vonoprazan dual therapy stood out for its high efficacy and lower incidence of adverse events. Thus, it is concluded that P-CABs represent a significant therapeutic advance, offering greater reliability in combating antimicrobial resistance. However, due to the scarcity of robust data on Latin American populations, future regional clinical trials and cost-effectiveness evaluations tailored to the reality of the Brazilian healthcare system become essential to substantiate new clinical guidelines.

Authors

Publication Details

Journal
Revista Goiana de Medicina
Published
2026-11-18
Primary Topic
Helicobacter pylori-related gastroenterology studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Eficácia de esquemas terapêuticos baseados em bloqueadores competitivos de potássio (P-CABS) na erradicação de cepas de Helicobacter pylori resistentes

Jullia Aquino da Silva, Ana Clara dos Santos Souza, Danielle de Oliveira Teixeira, Waldemar Nunes da Silva Queiroz Neto et al.
Revista Goiana de Medicina
Helicobacter pylori-related gastroenterology studies
article

Eficácia de esquemas terapêuticos baseados em bloqueadores competitivos de potássio (P-CABS) na erradicação de cepas de Helicobacter pylori resistentes

Jullia Aquino da Silva, Ana Clara dos Santos Souza, Danielle de Oliveira Teixeira, Waldemar Nunes da Silva Queiroz Neto, Bruna Dell’Acqua Cassão Rezende
article en

Abstract

Helicobacter pylori infection is a severe public health issue, characterized by high prevalence in Latin America and a strong association with the development of gastric cancer. Given the growing bacterial resistance to conventional therapy based on proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs) emerge as a promising alternative. The present study aims to evaluate the efficacy of P-CABs, focusing on vonoprazan and tegoprazan, in the eradication of resistant H. pylori strains compared to PPIs. To this end, a literature review was conducted in the PubMed/MEDLINE, Embase, Cochrane, and Web of Science databases, encompassing publications particularly from the last 10 years. The results indicate that P-CABs promote faster, more potent, and sustained acid suppression without being subjected to interference from CYP2C19 polymorphisms. Vonoprazan-based regimens achieve overall eradication rates of 86% to 94%, outperforming PPIs, especially in clarithromycin-resistant strains (66% to 81% efficacy against 32% to 40% for PPIs). Highdose vonoprazan dual therapy stood out for its high efficacy and lower incidence of adverse events. Thus, it is concluded that P-CABs represent a significant therapeutic advance, offering greater reliability in combating antimicrobial resistance. However, due to the scarcity of robust data on Latin American populations, future regional clinical trials and cost-effectiveness evaluations tailored to the reality of the Brazilian healthcare system become essential to substantiate new clinical guidelines.

Revista Goiana de Medicina
Helicobacter pylori-related gastroenterology studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon